Medable has launched Agent Studio, which it describes as the first agentic artificial intelligence (AI) platform designed specifically for life sciences. Alongside the launch, the company has introduced CRA Agent, a monitoring tool built on the platform and aimed at supporting clinical trial oversight.

Agent Studio is a no-code system that allows clinical teams to configure AI agents for specific tasks. According to the company, the aim is to reduce inefficiencies in clinical development, particularly in areas such as protocol development, planning and optimisation. Medable said the system maintains human-in-the-loop oversight and aligns with regulatory and operational standards, while integrating with electronic data capture and enterprise systems including Veeva, Salesforce and Microsoft.

Michelle Longmire, chief executive officer and co-founder of Medable, said: “Agent Studio frees teams from the bottlenecks of legacy systems, accelerates trials, reduces costs, and ultimately helps bring medicines to patients faster.”

The company said CRA Agent, the first pre-built tool on the platform, aggregates and summarises data across trial systems, supports oversight of critical areas, and automates routine monitoring and communication, allowing clinical research associates to focus on higher-value tasks.

Tim Smith, chief technology officer and co-founder of Medable, added: “Agent Studio, designed specifically for the inherent complexities of this industry, will solve longstanding problems and allow the industry to completely re-imagine drug development.”

Clinical research has long faced delays caused by administrative processes and coordination across systems. Medable said the launch of Agent Studio is part of its broader strategy to streamline development and move closer to its vision of faster trial start-up, recruitment and execution.

Whether the use of agentic AI in clinical research can deliver the efficiencies Medable hopes for will become clearer as the platform is adopted.